

Alessandro Gronchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4647233/publications.pdf>

Version: 2024-02-01

462
papers

31,973
citations

2544

96
h-index

6131

159
g-index

469
all docs

469
docs citations

469
times ranked

17939
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases. Journal of Thoracic and Cardiovascular Surgery, 1997, 113, 37-49.	0.8	1,451
2	Soft tissue and visceral sarcomas: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv51-iv67.	1.2	641
3	Consensus meeting for the management of gastrointestinal stromal tumorsâ€“ Report of the GIST Consensus Conference of 20â€“21 March 2004, under the auspices of ESMO. Annals of Oncology, 2005, 16, 566-578.	1.2	628
4	Early lung-cancer detection with spiral CT and positron emission tomography in heavy smokers: 2-year results. Lancet, The, 2003, 362, 593-597.	13.7	422
5	Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncology, The, 2007, 8, 595-602.	10.7	416
6	Gastrointestinal stromal tumours: ESMOâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv68-iv78.	1.2	413
7	Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients. Journal of Clinical Oncology, 2009, 27, 24-30.	1.6	410
8	Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS). Annals of Surgery, 2016, 263, 1002-1009.	4.2	392
9	Annual or biennial CT screening versus observation in heavy smokers. European Journal of Cancer Prevention, 2012, 21, 308-315.	1.3	381
10	Soft tissue and visceral sarcomas: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upâ†. Annals of Oncology, 2021, 32, 1348-1365.	1.2	381
11	Bone sarcomas: ESMOâ€“PaedCanâ€“EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2018, 29, iv79-iv95.	1.2	380
12	Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-ST5 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncology, The, 2017, 18, 812-822.	10.7	370
13	A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology, 2004, 127, 294-299.	1.3	363
14	Rhabdomyosarcoma in adults. Cancer, 2003, 98, 571-580.	4.1	360
15	NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)â€“Update of the NCCN Clinical Practice Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, S-1-S-29.	4.9	360
16	Malignant peripheral nerve sheath tumors. Cancer, 2006, 107, 1065-1074.	4.1	358
17	Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. Cancer, 2004, 101, 627-634.	4.1	345
18	Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment. Annals of Surgical Oncology, 2009, 16, 2587-2593.	1.5	334

#	ARTICLE	IF	CITATIONS
19	Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2003, 21, 1390-1397.	1.6	326
20	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 671-680.	10.7	318
21	NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2â€³3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 1148-1159.	10.7	288
22	An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma Patients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). <i>Annals of Oncology</i> , 2017, 28, 2399-2408.	1.2	274
23	Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 200-229.	329.8	273
24	Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. <i>Journal of Clinical Oncology</i> , 2013, 31, 1649-1655.	1.6	268
25	Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1366-1377.	10.7	266
26	Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control. <i>Annals of Surgical Oncology</i> , 2010, 17, 1507-1514.	1.5	257
27	Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution. <i>Annals of Surgery</i> , 2010, 251, 506-511.	4.2	253
28	Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells. <i>Cancer Research</i> , 2010, 70, 2235-2244.	0.9	251
29	Imatinib mesylate in chordoma. <i>Cancer</i> , 2004, 101, 2086-2097.	4.1	250
30	Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2005, 23, 96-104.	1.6	248
31	The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 96-107.	2.8	243
32	Low-dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis. <i>Cancer</i> , 2001, 92, 1259-1264.	4.1	237
33	Phase II Study of Imatinib in Advanced Chordoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 914-920.	1.6	230
34	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma. <i>JAMA Oncology</i> , 2018, 4, 483.	7.1	227
35	Gastrointestinal stromal tumours: ESMOâ€“EURACANâ€“GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2022, 33, 20-33.	1.2	213
36	Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTCâ€“STBSG. <i>Annals of Surgical Oncology</i> , 2012, 19, 2981-2991.	1.5	212

#	ARTICLE	IF	CITATIONS
37	Surgery of Residual Disease Following Molecular-targeted Therapy With Imatinib Mesylate in Advanced/Metastatic GIST. <i>Annals of Surgery</i> , 2007, 245, 341-346.	4.2	206
38	Chordoma: Natural History and Results in 28 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2003, 10, 291-296.	1.5	204
39	NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2007, 5 Suppl 2, S1-29; quiz S30.	4.9	201
40	Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 720-725.	1.5	199
41	High-Grade Soft-Tissue Sarcomas: Tumor Response Assessment—Pilot Study to Assess the Correlation between Radiologic and Pathologic Response by Using RECIST and Choi Criteria. <i>Radiology</i> , 2009, 251, 447-456.	7.3	198
42	Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate. <i>Journal of Clinical Oncology</i> , 2005, 23, 7669-7675.	1.6	196
43	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors (GIST): The EORTC STBSG Experience. <i>Annals of Surgical Oncology</i> , 2013, 20, 2937-2943.	1.5	190
44	Management of sporadic desmoid-type fibromatosis: A European consensus approach based on patients' and professionals' expertise – A Sarcoma Patients EuroNet and European Organisation for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group initiative. <i>European Journal of Cancer</i> , 2015, 51, 127-136.	2.8	188
45	Spontaneous Regression of Primary Abdominal Wall Desmoid Tumors: More Common than Previously Thought. <i>Annals of Surgical Oncology</i> , 2013, 20, 4096-4102.	1.5	187
46	Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. <i>Annals of Oncology</i> , 2011, 22, 1682-1690.	1.2	185
47	Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. <i>Cancer</i> , 2005, 103, 402-408.	4.1	182
48	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	1.2	180
49	Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group. <i>Annals of Oncology</i> , 2017, 28, 1230-1242.	1.2	168
50	Retroperitoneal soft tissue sarcomas. <i>Cancer</i> , 2004, 100, 2448-2455.	4.1	167
51	CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence. <i>Cancer</i> , 2013, 119, 3696-3702.	4.1	162
52	Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 449-457.	4.1	160
53	Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers. <i>Annals of Surgical Oncology</i> , 2010, 17, 211-219.	1.5	159
54	Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1. <i>Clinical Cancer Research</i> , 2008, 14, 4550-4555.	7.0	158

#	ARTICLE	IF	CITATIONS
55	Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST). <i>European Journal of Surgical Oncology</i> , 2009, 35, 739-745.	1.0	156
56	Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas: A Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 850-856.	1.6	156
57	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 1447-1454.	1.5	152
58	Bone sarcomas: ESMOâ€“EURACANâ€“GENTURISâ€“ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 1520-1536.	1.2	150
59	Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasmâ€“a position paper from the Italian and the French Sarcoma Group. <i>Annals of Oncology</i> , 2014, 25, 578-583.	1.2	149
60	Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> , 2015, 33, 4276-4283.	1.6	148
61	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , 2017, 35, 1713-1720.	1.6	148
62	Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. <i>Acta Oncol</i> , 2017, 56, 88-92.	1.8	146
63	Myxoid/round cell and pleomorphic liposarcomas. <i>Cancer</i> , 2007, 109, 2522-2531.	4.1	145
64	Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. <i>Journal of Clinical Oncology</i> , 2020, 38, 2178-2186.	1.6	145
65	Chordoma. <i>Current Opinion in Oncology</i> , 2007, 19, 367-370.	2.4	144
66	Response to imatinib plus sirolimus in advanced chordoma. <i>Annals of Oncology</i> , 2009, 20, 1886-1894.	1.2	142
67	Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma. <i>Annals of Surgery</i> , 2018, 267, 959-964.	4.2	142
68	Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2006, 13, 110-117.	1.5	141
69	Sunitinib malate in solitary fibrous tumor (SFT). <i>Annals of Oncology</i> , 2012, 23, 3171-3179.	1.2	140
70	Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma. <i>Clinical Cancer Research</i> , 2009, 15, 1096-1104.	7.0	138
71	Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas. <i>Clinical Cancer Research</i> , 2006, 12, 6920-6928.	7.0	135
72	Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. <i>Annals of Oncology</i> , 2014, 25, 2425-2432.	1.2	135

#	ARTICLE	IF	CITATIONS
73	The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial. <i>European Journal of Cancer</i> , 2019, 109, 51-60.	2.8	134
74	Sporadic extra abdominal wall desmoid-type fibromatosis: Surgical resection can be safely limited to a minority of patients. <i>European Journal of Cancer</i> , 2015, 51, 186-192.	2.8	133
75	Mesenchymal chondrosarcoma: Prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. <i>European Journal of Cancer</i> , 2015, 51, 374-381.	2.8	133
76	Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan. <i>Journal of Clinical Oncology</i> , 2005, 23, 4021-4030.	1.6	130
77	Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. <i>Annals of Oncology</i> , 2012, 23, 771-776.	1.2	129
78	Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?. <i>Annals of Oncology</i> , 2010, 21, 403-408.	1.2	128
79	Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib â€“ Analysis of prognostic factors (EORTC-STBSG collaborative study). <i>European Journal of Surgical Oncology</i> , 2014, 40, 412-419.	1.0	125
80	Phase II study on lapatinib in advanced EGFR-positive chordoma. <i>Annals of Oncology</i> , 2013, 24, 1931-1936.	1.2	122
81	Aggressive fibromatosis in children and adolescents. <i>Cancer</i> , 2010, 116, 233-240.	4.1	121
82	Natural History of Imatinib-naïve GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1646-1656.	3.7	116
83	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. <i>Cancer Research</i> , 2006, 66, 8918-8924.	0.9	115
84	Outcome of chemotherapy in advanced synovial sarcoma patients: Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancerâ€Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity. <i>European Journal of Cancer</i> , 2016, 58, 62-72.	2.8	114
85	Epithelioid sarcoma in children and adolescents. <i>Cancer</i> , 2006, 106, 708-717.	4.1	112
86	Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. <i>Annals of Oncology</i> , 2009, 20, 1439-1444.	1.2	112
87	Mode of action of trabectedin in myxoid liposarcomas. <i>Oncogene</i> , 2014, 33, 5201-5210.	5.9	111
88	Gastrointestinal Stromal Tumor of the Rectum: Results of Surgical and Multimodality Therapy in the Era of Imatinib. <i>Annals of Surgical Oncology</i> , 2013, 20, 586-592.	1.5	110
89	Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 415-429.	3.2	110
90	Soft tissue sarcoma nomograms and their incorporation into practice. <i>Cancer</i> , 2017, 123, 2802-2820.	4.1	105

#	ARTICLE	IF	CITATIONS
91	Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7873-7888.	1.5	105
92	Postâ€relapse outcomes after primary extended resection of retroperitoneal sarcoma: A report from the Transâ€Atlantic RPS Working Group. <i>Cancer</i> , 2017, 123, 1971-1978.	4.1	104
93	Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. <i>Cancer</i> , 2004, 100, 1943-1950.	4.1	103
94	Surgical Technique, Morbidity, and Outcome of Primary Retroperitoneal Sarcoma Involving Inferior Vena Cava. <i>Annals of Surgical Oncology</i> , 2012, 19, 511-518.	1.5	102
95	Myogenic Differentiation and Histologic Grading Are Major Prognostic Determinants in Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2015, 39, 383-393.	3.7	101
96	Radiomic analysis of soft tissues sarcomas can distinguish intermediate from highâ€grade lesions. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 47, 829-840.	3.4	100
97	Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancerâ€Soft Tissue and Bone Sarcoma Group (EORTCâ€STBSG) recommendations for pathological examination and reporting. <i>European Journal of Cancer</i> , 2016, 53, 84-95.	2.8	99
98	Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. <i>Oncogene</i> , 2006, 25, 6140-6146.	5.9	98
99	Tenosynovial giant cell tumour/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. <i>European Journal of Cancer</i> , 2015, 51, 210-217.	2.8	97
100	Ultraâ€rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. <i>Cancer</i> , 2021, 127, 2934-2942.	4.1	96
101	External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2018, 25, 754-767.	1.5	95
102	Histologyâ€specific nomogram for primary retroperitoneal soft tissue sarcoma. <i>Cancer</i> , 2010, 116, 2429-2436.	4.1	93
103	Desmoid-Type Fibromatosis and Pregnancy. <i>Annals of Surgery</i> , 2014, 259, 973-978.	4.2	93
104	High-grade Sarcomatous Overgrowth in Solitary Fibrous Tumors. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1202-1215.	3.7	91
105	Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. <i>Annals of Oncology</i> , 2016, 27, 2283-2288.	1.2	90
106	Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis. <i>British Journal of Surgery</i> , 2017, 104, 347-357.	0.3	89
107	Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas. <i>Neuro-Oncology</i> , 2010, 12, 776-789.	1.2	88
108	Alveolar Soft Part Sarcoma: Clinical Presentation, Treatment, and Outcome in a Series of 33 Patients at a Single Institution. <i>Annals of Surgical Oncology</i> , 2010, 17, 3229-3233.	1.5	87

#	ARTICLE	IF	CITATIONS
109	Epithelioid Sarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 3542-3551.	1.5	86
110	Resectable extra-pleural and extra-meningeal solitary fibrous tumours: A multi-centre prognostic study. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1064-1070.	1.0	86
111	Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>Cancer</i> , 2020, 126, 2637-2647.	4.1	86
112	Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. <i>Cancer</i> , 2012, 118, 5857-5866.	4.1	85
113	Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2010, 17, 3220-3228.	1.5	83
114	Sunitinib Malate and Figitumumab in Solitary Fibrous Tumor: Patterns and Molecular Bases of Tumor Response. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1286-1297.	4.1	83
115	Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as Potential Targets in Treating Aggressive Fibromatosis. <i>Clinical Cancer Research</i> , 2007, 13, 5034-5040.	7.0	82
116	The prognostic impact of dedifferentiation in retroperitoneal liposarcoma. <i>Cancer</i> , 2008, 113, 1657-1665.	4.1	81
117	Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. <i>Clinical Sarcoma Research</i> , 2013, 3, 4.	2.3	81
118	Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase II study from the Italian Sarcoma Group. <i>European Journal of Cancer</i> , 2014, 50, 784-792.	2.8	80
119	Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. <i>Clinical Cancer Research</i> , 2019, 25, 2664-2671.	7.0	80
120	Imatinib in advanced chordoma: A retrospective case series analysis. <i>European Journal of Cancer</i> , 2015, 51, 2609-2614.	2.8	78
121	Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP). <i>Clinical Cancer Research</i> , 2016, 22, 837-846.	7.0	78
122	Response to chemotherapy of solitary fibrous tumour: A retrospective study. <i>European Journal of Cancer</i> , 2013, 49, 2376-2383.	2.8	77
123	Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. <i>Annals of Oncology</i> , 2015, 26, 300-306.	1.2	77
124	External validation of a multi-institutional retroperitoneal sarcoma nomogram. <i>Cancer</i> , 2016, 122, 1417-1424.	4.1	77
125	Activity of sunitinib in extraskeletal myxoid chondrosarcoma. <i>European Journal of Cancer</i> , 2014, 50, 1657-1664.	2.8	74
126	Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. <i>Spine</i> , 2016, 41, 1049-1057.	2.0	74

#	ARTICLE	IF	CITATIONS
127	PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor. <i>Neuro-Oncology</i> , 2009, 11, 725-736.	1.2	71
128	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 86-91.	2.0	71
129	Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. <i>BMC Medicine</i> , 2017, 15, 109.	5.5	71
130	Radiotherapy for retroperitoneal liposarcoma: A report from the Transatlantic Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2019, 125, 1290-1300.	4.1	71
131	Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): Interim analysis of a randomised phase III trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 10008-10008.	1.6	71
132	Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure. <i>Annals of Surgical Oncology</i> , 2007, 14, 1583-1590.	1.5	70
133	Denosumab treatment of inoperable or locally advanced giant cell tumor of bone “ Multicenter analysis outside clinical trial. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1384-1390.	1.0	70
134	Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas). <i>Clinical Cancer Research</i> , 2019, 25, 5295-5300.	7.0	70
135	Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. <i>Annals of Oncology</i> , 2013, 24, 817-823.	1.2	69
136	p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. <i>Clinical Cancer Research</i> , 2003, 9, 4132-8.	7.0	69
137	Dermatofibrosarcoma protuberans-derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib. <i>International Journal of Cancer</i> , 2011, 129, 1761-1772.	5.1	68
138	Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-À-vis Temozolomide and Antiangiogenics. <i>Clinical Cancer Research</i> , 2013, 19, 5192-5201.	7.0	67
139	Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. <i>Modern Pathology</i> , 2015, 28, 1074-1083.	5.5	67
140	Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients. <i>European Journal of Cancer</i> , 2017, 74, 9-16.	2.8	67
141	Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1071-1083.	1.0	66
142	Quadruple-Negative GIST Is a Sentinel for Unrecognized Neurofibromatosis Type 1 Syndrome. <i>Clinical Cancer Research</i> , 2017, 23, 273-282.	7.0	66
143	Carney triad: case report and molecular analysis of gastric tumor. <i>Human Pathology</i> , 2005, 36, 112-116.	2.0	65
144	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. <i>ESMO Open</i> , 2021, 6, 100170.	4.5	65

#	ARTICLE	IF	CITATIONS
145	STRASS (EORTC 62092): A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma.. Journal of Clinical Oncology, 2019, 37, 11001-11001.	1.6	64
146	Surgical treatment of locally recurrent rectal carcinoma. Diseases of the Colon and Rectum, 1997, 40, 1421-1424.	1.3	63
147	Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. Annals of Oncology, 2013, 24, 2181-2189.	1.2	63
148	KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naïve Localized GIST. American Journal of Surgical Pathology, 2015, 39, 922-930.	3.7	63
149	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. JAMA Oncology, 2018, 4, e180219.	7.1	63
150	Expression of Ligand-Activated KIT and Platelet-Derived Growth Factor Receptor \hat{I}^2 Tyrosine Kinase Receptors in Synovial Sarcoma. Clinical Cancer Research, 2004, 10, 938-943.	7.0	62
151	Novel method to detect microRNAs using chip-based QuantStudio 3D digital PCR. BMC Genomics, 2015, 16, 849.	2.8	62
152	Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution. Annals of Surgical Oncology, 2007, 14, 553-559.	1.5	61
153	c-Kit/PDGFR α Gene Status Alterations Possibly Related to Primary Imatinib Resistance in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2007, 13, 2369-2377.	7.0	60
154	Assessment of Circulating microRNAs in Plasma of Lung Cancer Patients. Molecules, 2014, 19, 3038-3054.	3.8	60
155	Desmoid-Type Fibromatosis. Surgical Oncology Clinics of North America, 2016, 25, 803-826.	1.5	60
156	Feasibility of Preoperative Chemotherapy With or Without Radiation Therapy in Localized Soft Tissue Sarcomas of Limbs and Superficial Trunk in the Italian Sarcoma Group/Grupo Espa�ol de Investigaci�n en Sarcomas Randomized Clinical Trial: Three Versus Five Cycles of Full-Dose Epirubicin Plus Ifosfamide. Journal of Clinical Oncology, 2015, 33, 3628-3634.	1.6	59
157	Clinical, Pathological and Surgical Characteristics of Duodenal Gastrointestinal Stromal Tumor and Their Influence on Survival: A Multi-Center Study. Annals of Surgical Oncology, 2012, 19, 3361-3367.	1.5	58
158	Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis. European Journal of Cancer, 2015, 51, 2800-2807.	2.8	58
159	SYT-SSX fusion genes and prognosis in synovial sarcoma. British Journal of Cancer, 2001, 85, 1535-1539.	6.4	56
160	9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for kit and platelet-derived growth factor receptor \hat{I}^2 gene alterations. Cancer, 2005, 104, 159-169.	4.1	56
161	Sirolimus in Advanced Epithelioid Hemangioendothelioma: A Retrospective Case-Series Analysis from the Italian Rare Cancer Network Database. Annals of Surgical Oncology, 2016, 23, 2735-2744.	1.5	56
162	Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centres. European Journal of Cancer, 2018, 105, 19-27.	2.8	56

#	ARTICLE	IF	CITATIONS
181	Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. <i>European Journal of Cancer</i> , 2007, 43, 2691-2697.	2.8	43
182	The “Rib-Like” Technique for Surgical Treatment of Sternal Tumors: Lessons Learned From 101 Consecutive Cases. <i>Annals of Thoracic Surgery</i> , 2011, 92, 1208-1216.	1.3	43
183	Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. <i>British Journal of Surgery</i> , 2015, 102, 1079-1087.	0.3	43
184	Desmoid tumors: To treat or not to treat, That is the question. <i>Cancer</i> , 2020, 126, 5213-5221.	4.1	43
185	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	1.2	42
186	Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. <i>EClinicalMedicine</i> , 2019, 17, 100215.	7.1	42
187	Current concepts and future perspectives in retroperitoneal soft-tissue sarcoma management. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 1145-1157.	2.4	41
188	Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. <i>Surgical Oncology</i> , 2016, 25, 125-131.	1.6	41
189	Surgical management of localized soft tissue tumors. <i>Cancer</i> , 2014, 120, 2638-2648.	4.1	40
190	Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event) <i>TJ ETQq0 0 0 rgBT / Overlock 10 Tf 50 37</i>	0.0	40
191	Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. <i>Cancer</i> , 2018, 124, 4056-4063.	4.1	40
192	Baseline C-Reactive Protein Level Predicts Survival of Early-Stage Lung Cancer: Evidence from a Systematic Review and Meta-Analysis. <i>Tumori</i> , 2016, 102, 441-449.	1.1	39
193	Radiation-Induced Sarcoma of the Head and Neck: A Review of the Literature. <i>Frontiers in Oncology</i> , 2018, 8, 449.	2.8	39
194	Personalizing surgical margins in retroperitoneal sarcomas: an update. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 613-631.	2.4	39
195	Extrameningeal solitary fibrous tumors—surgery alone or surgery plus perioperative radiotherapy: A retrospective study from the global solitary fibrous tumor initiative in collaboration with the Sarcoma Patients EuroNet. <i>Cancer</i> , 2020, 126, 3002-3012.	4.1	39
196	Lack of SYT-SSX Fusion Transcripts in Malignant Peripheral Nerve Sheath Tumors on RT-PCR Analysis of 34 Archival Cases. <i>Laboratory Investigation</i> , 2002, 82, 609-618.	3.7	38
197	Gastrointestinal Stromal Tumors I: Pathology, Pathobiology, Primary Therapy, and Surgical Issues. <i>Seminars in Oncology</i> , 2009, 36, 290-301.	2.2	38
198	Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. <i>Clinical Sarcoma Research</i> , 2013, 3, 8.	2.3	38

#	ARTICLE	IF	CITATIONS
199	<scp>HSPA</scp>8 as a novel fusion partner of <scp>NR</scp>4<scp>A</scp>3 in extraskeletal myxoid chondrosarcoma. Genes Chromosomes and Cancer, 2017, 56, 582-586.	2.8	38
200	Has the Outcome for Patients Who Undergo Resection of Primary Retroperitoneal Sarcoma Changed Over Time? A Study of Time Trends During the Past 15 Years. Annals of Surgical Oncology, 2021, 28, 1700-1709.	1.5	38
201	Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. Journal of Pathology, 2007, 212, 227-235.	4.5	37
202	Tumor response to sunitinib malate observed in clear-cell sarcoma. Annals of Oncology, 2010, 21, 1130-1131.	1.2	37
203	Surgery in Retroperitoneal Soft Tissue Sarcoma: A Call for a Consensus Between Europe and North America. Annals of Surgical Oncology, 2011, 18, 2107-2110.	1.5	37
204	Indications for surgery in advanced/metastatic GIST. European Journal of Cancer, 2016, 63, 154-167.	2.8	37
205	(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. European Journal of Cancer, 2017, 70, 1-11.	2.8	37
206	Quality of Local Treatment or Biology of the Tumor: Which are the Trump Cards for Loco-regional Control of Retroperitoneal Sarcoma?. Annals of Surgical Oncology, 2013, 20, 2111-2113.	1.5	36
207	Correlation between radiological assessment and histopathological diagnosis in retroperitoneal tumors: Analysis of 291 consecutive patients at a tertiary reference sarcoma center. European Journal of Surgical Oncology, 2014, 40, 1662-1670.	1.0	36
208	Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study. Clinical Sarcoma Research, 2013, 3, 16.	2.3	34
209	Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis. British Journal of Surgery, 2014, 101, 1674-1680.	0.3	34
210	Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer. European Journal of Cancer, 2017, 79, 90-97.	2.8	34
211	Diagnostic accuracy of percutaneous biopsy in retroperitoneal sarcoma. British Journal of Surgery, 2019, 106, 395-403.	0.3	34
212	Activate and resist: L576P-KIT in GIST. Molecular Cancer Therapeutics, 2009, 8, 2491-2495.	4.1	33
213	Perioperative Management of Extremity Soft Tissue Sarcomas. Journal of Clinical Oncology, 2018, 36, 118-124.	1.6	33
214	Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. JAMA Oncology, 2020, 6, 535.	7.1	33
215	Personalizing surgical margins in retroperitoneal sarcomas. Expert Review of Anticancer Therapy, 2015, 15, 553-567.	2.4	32
216	Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-ESBTS). International Journal of Cancer, 2018, 142, 2610-2620.	5.1	32

#	ARTICLE	IF	CITATIONS
217	Treatment of Desmoid Tumors in 2019. <i>JAMA Oncology</i> , 2019, 5, 567.	7.1	32
218	Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. <i>European Journal of Cancer</i> , 2019, 106, 225-233.	2.8	32
219	Adjuvant treatment of GIST with imatinib: Solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS). <i>European Journal of Cancer</i> , 2009, 45, 1103-1106.	2.8	31
220	Absence of progression, not extent of tumour shrinkage, defines prognosis in soft-tissue sarcoma – An analysis of the EORTC 62012 study of the EORTC STBSC. <i>European Journal of Cancer</i> , 2016, 64, 44-51.	2.8	31
221	The Prognostic Role of β -Catenin Mutations in Desmoid-type Fibromatosis Undergoing Resection Only. <i>Annals of Surgery</i> , 2021, 273, 1094-1101.	4.2	31
222	Fluorodeoxyglucose Uptake Measured by Positron Emission Tomography and Standardized Uptake Value Predicts Long-Term Survival of CT Screening Detected Lung Cancer in Heavy Smokers. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1352-1356.	1.1	30
223	Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. <i>BMC Cancer</i> , 2010, 10, 254.	2.6	30
224	The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor. <i>Cancer</i> , 2010, 116, 1847-1858.	4.1	30
225	MRP1 Overexpression Determines Poor Prognosis in Prospectively Treated Patients with Localized High-Risk Soft Tissue Sarcoma of Limbs and Trunk Wall: An ISG/GEIS Study. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 249-259.	4.1	30
226	Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Cancer</i> , 2021, 127, 729-738.	4.1	30
227	Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. <i>Acta Oncologica</i> , 2017, 56, 1013-1020.	1.8	29
228	Adaptive Immunity in Fibrosarcomatous Dermatofibrosarcoma Protuberans and Response to Imatinib Treatment. <i>Journal of Investigative Dermatology</i> , 2017, 137, 484-493.	0.7	29
229	European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Experience with Advanced/Metastatic Epithelioid Sarcoma Patients Treated in Prospective Trials: Clinical Profile and Response to Systemic Therapy. <i>Clinical Oncology</i> , 2018, 30, 448-454.	1.4	29
230	Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib. <i>JAMA Surgery</i> , 2020, 155, e200397.	4.3	29
231	Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with soft tissue sarcoma: Results of a retrospective multicenter study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2166-2172.	1.0	29
232	SELNET clinical practice guidelines for soft tissue sarcoma and GIST. <i>Cancer Treatment Reviews</i> , 2022, 102, 102312.	7.7	29
233	Prognostic Factors and Outcome of Spermatic Cord Sarcoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 3557-3563.	1.5	28
234	β -Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression. <i>Molecular Oncology</i> , 2017, 11, 1495-1507.	4.6	28

#	ARTICLE	IF	CITATIONS
235	Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. <i>European Journal of Surgical Oncology</i> , 2018, 44, 810-815.	1.0	28
236	Evidence of Neural Differentiation in a Case of Post-therapy Primitive Neuroectodermal Tumor/Ewing Sarcoma of Bone. <i>American Journal of Surgical Pathology</i> , 2003, 27, 1161-1166.	3.7	27
237	Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib. <i>Clinical Sarcoma Research</i> , 2012, 2, 22.	2.3	27
238	The Combination of Surgery and Imatinib in GIST: A Reality for Localized Tumors at High Risk, an Open Issue for Metastatic Ones. <i>Annals of Surgical Oncology</i> , 2012, 19, 1051-1055.	1.5	27
239	<i>AKT</i> and <i>BRAF</i> mutations in pediatric aggressive fibromatosis. <i>Cancer Medicine</i> , 2016, 5, 1204-1213.	2.8	27
240	NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. <i>Journal of Pathology</i> , 2019, 249, 90-101.	4.5	27
241	Treatment challenges in and outside a network setting: Soft tissue sarcomas. <i>European Journal of Surgical Oncology</i> , 2019, 45, 31-39.	1.0	27
242	Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management. <i>Cancers</i> , 2020, 12, 2703.	3.7	27
243	Patient-derived solitary fibrous tumour xenografts predict high sensitivity to doxorubicin/dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumour. <i>European Journal of Cancer</i> , 2017, 76, 84-92.	2.8	26
244	Treatment of soft tissue sarcoma: a focus on earlier stages. <i>Future Oncology</i> , 2017, 13, 13-21.	2.4	26
245	Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. <i>Oncologist</i> , 2019, 24, e536-e541.	3.7	26
246	Postoperative Morbidity After Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 2705-2714.	1.5	26
247	Hyperthermia as an adjunctive treatment for soft-tissue sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2009, 9, 199-210.	2.4	25
248	Risk stratification models and mutational analysis: Keys to optimising adjuvant therapy in patients with gastrointestinal stromal tumour. <i>European Journal of Cancer</i> , 2013, 49, 884-892.	2.8	25
249	Evolution of Dermatofibrosarcoma Protuberans to DFSP-Derived Fibrosarcoma: An Event Marked by Epithelial-Mesenchymal Transition-like Process and 22q Loss. <i>Molecular Cancer Research</i> , 2016, 14, 820-829.	3.4	25
250	Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials. <i>Oncologist</i> , 2018, 23, 1250-1259.	3.7	25
251	Novel Models of Myxoid Liposarcoma Xenografts Mimicking the Biological and Pharmacologic Features of Human Tumors. <i>Clinical Cancer Research</i> , 2010, 16, 4958-4967.	7.0	24
252	Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STs) Protocol 0303. <i>Annals of Surgical Oncology</i> , 2017, 24, 3872-3879.	1.5	24

#	ARTICLE	IF	CITATIONS
253	Extraskelatal Myxoid Chondrosarcoma with Molecularly Confirmed Diagnosis: A Multicenter Retrospective Study Within the Italian Sarcoma Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 1142-1150.	1.5	23
254	Receptor tyrosine kinase pathway analysis sheds light on similarities between clearâ€cell sarcoma and metastatic melanoma. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 111-126.	2.8	22
255	Adequate Local Control in High-Risk Soft Tissue Sarcoma of the Extremity Treated with Surgery Alone at a Reference Centre: Should Radiotherapy Still be a Standard?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1536-1543.	1.5	22
256	Outcome of ilioaval resection and reconstruction for retroperitoneal sarcoma. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2019, 7, 547-556.	1.6	22
257	Surgical management of retroperitoneal sarcoma and opportunities for global collaboration. <i>Chinese Clinical Oncology</i> , 2018, 7, 39-39.	1.2	22
258	Is Autophagy Rather Than Apoptosis the Regression Driver in Imatinib-Treated Gastrointestinal Stromal Tumors?. <i>Translational Oncology</i> , 2008, 1, 177-186.	3.7	21
259	Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. <i>Neuro-Oncology</i> , 2012, 14, 736-744.	1.2	21
260	Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. <i>British Journal of Cancer</i> , 2014, 111, 1350-1362.	6.4	21
261	Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft. <i>Cancers</i> , 2019, 11, 1015.	3.7	21
262	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societ��) Tj ETQq0 0 0,rgBT /Overlock 10 Tf	2.8	21
263	Patterns of recurrence and survival probability after second recurrence of retroperitoneal sarcoma: A study from TARPSWG. <i>Cancer</i> , 2020, 126, 4917-4925.	4.1	21
264	A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4027-4032.	7.0	21
265	Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). <i>Current Treatment Options in Oncology</i> , 2012, 13, 277-284.	3.0	20
266	Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. <i>British Journal of Cancer</i> , 2017, 117, 340-346.	6.4	20
267	Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. <i>Clinical Sarcoma Research</i> , 2017, 7, 16.	2.3	20
268	Sulphurous thermal water inhalation impacts respiratory metabolic parameters in heavy smokers. <i>International Journal of Biometeorology</i> , 2019, 63, 1209-1216.	3.0	20
269	Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 2025-2032.	1.5	20
270	Oncogenic and ligand��dependent activation of KIT/PDGFRA in surgical samples of imatinib��treated gastrointestinal stromal tumours (GISTs). <i>Journal of Pathology</i> , 2009, 217, 103-112.	4.5	19

#	ARTICLE	IF	CITATIONS
271	Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum. Expert Review of Anticancer Therapy, 2012, 12, 1079-1087.	2.4	19
272	Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e566-e575.	3.8	19
273	Analysis of Differentiation Changes and Outcomes at Time of First Recurrence of Retroperitoneal Liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Annals of Surgical Oncology, 2021, 28, 7854-7863.	1.5	19
274	Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. European Journal of Surgical Oncology, 2008, 34, 720-724.	1.0	18
275	Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: An imaging, biochemical and molecular modeling study. International Journal of Cancer, 2011, 128, 983-990.	5.1	18
276	Working to improve the management of sarcoma patients across Europe: a policy checklist. BMC Cancer, 2018, 18, 424.	2.6	18
277	Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. Genes Chromosomes and Cancer, 2018, 57, 495-503.	2.8	18
278	Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study. Clinical Cancer Research, 2022, 28, 1672-1679.	7.0	18
279	Feasibility of Peritonectomy Associated with Intraperitoneal Hyperthermic Perfusion in Patients with Pseudomyxoma Peritonei. Tumori, 2002, 88, 370-375.	1.1	17
280	Atypical pleomorphic epithelioid angiomyolipoma localized to the pelvis: a case report and review of the literature. Histopathology, 2004, 44, 292-295.	2.9	17
281	In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas. Laboratory Investigation, 2013, 93, 1232-1240.	3.7	17
282	Axial skeletal osteosarcoma: a 25-year monoinstitutional experience in children and adolescents. Medical Oncology, 2014, 31, 875.	2.5	17
283	Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. BMC Cancer, 2016, 16, 686.	2.6	17
284	Morcellator's Port-site Metastasis of a Uterine Smooth Muscle Tumor of Uncertain Malignant Potential After Minimally Invasive Myomectomy. Journal of Minimally Invasive Gynecology, 2016, 23, 647-649.	0.6	17
285	Pharmacological therapies for Liposarcoma. Expert Review of Clinical Pharmacology, 2017, 10, 361-377.	3.1	17
286	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. Oncotarget, 2017, 8, 60036-60045.	1.8	17
287	The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. European Journal of Surgical Oncology, 2020, 46, 1320-1326.	1.0	17
288	Localised thoracic sarcomas: Outcome improvement over time at a single institution. European Journal of Cancer, 2013, 49, 2689-2697.	2.8	16

#	ARTICLE	IF	CITATIONS
289	Inoperable Primary Retroperitoneal Sarcomas: Clinical Characteristics and Reasons Against Resection at a Single Referral Institution. <i>Annals of Surgical Oncology</i> , 2021, 28, 1151-1157.	1.5	16
290	Unplanned Excision of Extremity and Trunk Wall Soft Tissue Sarcoma: To Re-resect or Not to Re-resect?. <i>Annals of Surgical Oncology</i> , 2021, 28, 4706-4717.	1.5	16
291	Identification of a gene expression driven progression pathway in myxoid liposarcoma. <i>Oncotarget</i> , 2014, 5, 5965-5977.	1.8	16
292	Optimal Approach to Sporadic Desmoid Tumors: From Radical Surgery to Observation. Time for a Consensus?. <i>Annals of Surgical Oncology</i> , 2012, 19, 3995-3997.	1.5	15
293	Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. Current Treatment Options in <i>Oncology</i> , 2013, 14, 415-424.	3.0	15
294	The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): “Red wine or white?”. <i>Annals of Surgical Oncology</i> , 2016, 23, 4418-4420.	1.5	15
295	Adjacent, Adherent, Invaded: A Spectrum of Biologic Aggressiveness Rather Than a Rationale for Selecting Organ Resection in Surgery of Primary Retroperitoneal Sarcomas. <i>Annals of Surgical Oncology</i> , 2018, 25, 13-16.	1.5	15
296	Historical perspectives and future directions in the surgical management of retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2018, 117, 7-11.	1.7	15
297	Combination of PPAR γ Agonist Pioglitazone and Trabectedin Induce Adipocyte Differentiation to Overcome Trabectedin Resistance in Myxoid Liposarcomas. <i>Clinical Cancer Research</i> , 2019, 25, 7565-7575.	7.0	15
298	Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors. <i>Clinical Cancer Research</i> , 2020, 26, 5534-5538.	7.0	15
299	Major vascular resection in retroperitoneal sarcoma surgery. <i>Surgery</i> , 2021, 170, 848-856.	1.9	15
300	Staging, nomograms and other predictive tools in retroperitoneal soft tissue sarcoma. <i>Chinese Clinical Oncology</i> , 2018, 7, 36-36.	1.2	15
301	Impact of chemotherapy in uterine sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other soft tissue sarcoma (STS) patients treated with first line chemotherapy. <i>Gynecologic Oncology</i> , 2016, 142, 95-101.	1.4	14
302	Accreditation for centers of sarcoma surgery. <i>Updates in Surgery</i> , 2017, 69, 1-7.	2.0	14
303	Management of meningeal solitary fibrous tumors/hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy?. <i>Acta Oncologica</i> , 2021, 60, 35-41.	1.8	14
304	A Prospective Observational Study of Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-Reported Outcomes 1 Year After Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 3904-3916.	1.5	14
305	Morbidity and Outcomes After Distal Pancreatectomy for Primary Retroperitoneal Sarcoma: An Analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 6882-6889.	1.5	14
306	Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. <i>Oncotarget</i> , 2018, 9, 18607-18626.	1.8	14

#	ARTICLE	IF	CITATIONS
307	Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092â€22092 STRASS trial. <i>Cancer</i> , 2022, 128, 2796-2805.	4.1	14
308	Uterine Sarcoma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion: a Feasibility Study. <i>Journal of Chemotherapy</i> , 2004, 16, 19-22.	1.5	13
309	ALTâ€associated promyelocytic leukaemia body (APB) detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcomas. <i>Journal of Pathology</i> , 2008, 214, 410-414.	4.5	13
310	Treatment of Localized Sarcomas. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 921-938.	2.2	13
311	Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. <i>Neuro-Oncology</i> , 2014, 16, 72-80.	1.2	13
312	A call to action: Why sarcoma surgery needs to be centralized. <i>Cancer</i> , 2018, 124, 4452-4454.	4.1	13
313	Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program. <i>Current Opinion in Oncology</i> , 2021, 33, 301-308.	2.4	13
314	Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult: An Updated Consensus Approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. <i>Annals of Surgical Oncology</i> , 2022, 29, 7335-7348.	1.5	13
315	Renal angiomyolipomas: At least two diseases. A series of patients treated at two European institutions. <i>European Journal of Surgical Oncology</i> , 2017, 43, 831-836.	1.0	12
316	Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach. <i>BioMed Research International</i> , 2018, 2018, 1-11.	1.9	12
317	Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma. <i>Anticancer Research</i> , 2018, 38, 3535-3542.	1.1	12
318	Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. <i>Lung Cancer</i> , 2019, 132, 17-23.	2.0	12
319	Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 869-875.	1.5	12
320	Individualizing Follow-Up Strategies in High-Grade Soft Tissue Sarcoma with Flexible Parametric Competing Risk Regression Models. <i>Cancers</i> , 2020, 12, 47.	3.7	12
321	Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin. <i>Cancers</i> , 2021, 13, 1453.	3.7	12
322	Oncological outcomes after major vascular resections for primary retroperitoneal liposarcoma. <i>European Journal of Surgical Oncology</i> , 2021, 47, 3004-3010.	1.0	12
323	Diagnosis strategy of adipocytic soft-tissue tumors in adults: a consensus from European experts. <i>European Journal of Surgical Oncology</i> , 2022, 48, 518-525.	1.0	12
324	Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients. <i>Annals of Surgical Oncology</i> , 2022, 29, 4376-4385.	1.5	12

#	ARTICLE	IF	CITATIONS
325	SELNET clinical practice guidelines for bone sarcoma. Critical Reviews in Oncology/Hematology, 2022, 174, 103685.	4.4	12
326	Combined modalities approach for localized adult extremity soft-tissue sarcoma. Expert Review of Anticancer Therapy, 2007, 7, 1135-1144.	2.4	11
327	Soft-tissue sarcomas of the extremities in patients of pediatric age. Journal of Children's Orthopaedics, 2007, 1, 195-203.	1.1	11
328	Desmoid-type fibromatosis: What works best?. European Journal of Cancer, 2009, 45, 466-467.	2.8	11
329	ILP and RT: The Study That Will Never Be. Annals of Surgical Oncology, 2011, 18, 303-305.	1.5	11
330	Thoracopleuropneumonectomy with Riblike Reconstruction for Recurrent Thoracic Sarcomas. Annals of Surgical Oncology, 2014, 21, 1610-1615.	1.5	11
331	The role of hyperthermic intraperitoneal chemotherapy (HIPEC) and isolated perfusion (ILP) interventions in sarcoma. Journal of Surgical Oncology, 2015, 111, 570-579.	1.7	11
332	Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. Acta Oncologica, 2018, 57, 1117-1126.	1.8	11
333	Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. Expert Opinion on Pharmacotherapy, 2019, 20, 1503-1515.	1.8	11
334	Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. ESMO Open, 2020, 5, e000604.	4.5	11
335	Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin downregulation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 83.	8.6	11
336	Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. European Journal of Cancer, 2021, 157, 291-300.	2.8	11
337	High CD133 expression levels in gastrointestinal stromal tumors. Cytometry Part B - Clinical Cytometry, 2011, 80B, 238-247.	1.5	10
338	Efficacy and Economic Value of Adjuvant Imatinib for Gastrointestinal Stromal Tumors. Oncologist, 2013, 18, 689-696.	3.7	10
339	Neoadjuvant treatment: a novel standard?. Current Opinion in Oncology, 2017, 29, 253-259.	2.4	10
340	The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk. JAMA Oncology, 2018, 4, 1167.	7.1	10
341	Intraperitoneal Invasion of Retroperitoneal Sarcomas: A Risk Factor for Dismal Prognosis. Annals of Surgical Oncology, 2019, 26, 3535-3541.	1.5	10
342	Improved Biopsy Accuracy in Retroperitoneal Dedifferentiated Liposarcoma. Annals of Surgical Oncology, 2020, 27, 4574-4581.	1.5	10

#	ARTICLE	IF	CITATIONS
343	Defining Which Patients Are at High Risk for Recurrence of Soft Tissue Sarcoma. Current Treatment Options in Oncology, 2020, 21, 56.	3.0	10
344	Treatment strategies and outcomes of primary Myxofibrosarcomas in a large patients cohort. European Journal of Surgical Oncology, 2022, 48, 1723-1729.	1.0	10
345	Gastrointestinal stromal tumors: evolving role of the multidisciplinary team approach in management. Expert Review of Anticancer Therapy, 2012, 12, 1053-1068.	2.4	9
346	Surgical Approach to Primary Tumors of the Chest Wall in Children and Adolescents: 30 Years of Mono-Institutional Experience. Tumori, 2016, 102, 89-95.	1.1	9
347	Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas can salvage a selected subgroup of patientsâ€”A propensity score analysis. Journal of Surgical Oncology, 2019, 119, 318-323.	1.7	9
348	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. Oncotarget, 2018, 9, 34617-34627.	1.8	9
349	Histology-tailored multidisciplinary management of primary retroperitoneal sarcomas. European Journal of Surgical Oncology, 2023, 49, 1061-1067.	1.0	9
350	Proteomic detection of a large amount of SCGF± in the stroma of GISTs after imatinib therapy. Journal of Translational Medicine, 2011, 9, 158.	4.4	8
351	Sensitivity of myxoid-round cell liposarcoma (MRCL) to trabectedin (T) may be related to a direct effect on the fusion transcript. Journal of Clinical Oncology, 2007, 25, 10000-10000.	1.6	8
352	Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomasâ€”Looking Forward. Cancers, 2022, 14, 1831.	3.7	8
353	Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor. Expert Review of Anticancer Therapy, 2022, 22, 491-503.	2.4	8
354	Current Status of Lung Cancer Screening. Thoracic Surgery Clinics, 2013, 23, 129-140.	1.0	7
355	Cytoreductive Surgery in Advanced GIST: Timing is Everything. Annals of Surgical Oncology, 2013, 20, 4059-4060.	1.5	7
356	Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): When abstention is better than care. Journal of Surgical Oncology, 2015, 111, 133-134.	1.7	7
357	MicroRNA Profile of Lung Tumor Tissues Is Associated with a High Risk Plasma miRNA Signature. Microarrays (Basel, Switzerland), 2016, 5, 18.	1.4	7
358	The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. Expert Review of Anticancer Therapy, 2016, 16, 473-484.	2.4	7
359	An Update on Non-extremity Soft Tissue Sarcomas. Clinical Oncology, 2017, 29, 516-527.	1.4	7
360	Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. British Journal of Cancer, 2019, 121, 464-473.	6.4	7

#	ARTICLE	IF	CITATIONS
361	Liver resection for sarcoma metastases: A systematic review and experience from two European centres. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1807-1813.	1.0	7
362	Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: A guide for surgical oncologists. <i>Journal of Surgical Oncology</i> , 2021, 123, 12-23.	1.7	7
363	Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase II trial in localized myxoid liposarcoma—A collaborative Spanish (GEIS), Italian (ISG) and French (FSG) group study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 11514-11514.	1.6	7
364	<scp>CINSARC</scp> in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the <scp>ISG&ST</scp> 1001 study. <i>Cancer Medicine</i> , 2023, 12, 1350-1357.	2.8	7
365	Adipose-Induced Retroperitoneal Soft Tissue Sarcoma Tumorigenesis: A Potential Crosstalk between Sarcoma and Fat Cells. <i>Molecular Cancer Research</i> , 2016, 14, 1254-1265.	3.4	6
366	High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma. <i>Sarcoma</i> , 2017, 2017, 1-5.	1.3	6
367	Prospective assessment of the predictive value of the <i>BRCA1</i> gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. <i>Cancer Medicine</i> , 2018, 7, 1575-1577.	2.8	6
368	Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. <i>European Journal of Cancer</i> , 2018, 94, 187-198.	2.8	6
369	Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should. <i>Annals of Surgical Oncology</i> , 2018, 25, 2129-2131.	1.5	6
370	2018 ESMO Sarcoma and GIST Symposium: “take-home messages” in soft tissue sarcoma. <i>ESMO Open</i> , 2018, 3, e000390.	4.5	6
371	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	3.7	6
372	The Landmark Series: Multimodality Treatment of Extremity Sarcoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3672-3682.	1.5	6
373	Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 571-576.	3.1	6
374	Severe Postoperative Complications are Associated with Impaired Survival in Primary but not in Recurrent Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 2693-2699.	1.5	6
375	Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis. <i>Cancer Medicine</i> , 2021, 10, 4356-4365.	2.8	6
376	Management of serious complications in intra-abdominal desmoid-type fibromatosis. <i>Cancer Reports</i> , 2021, 4, e1411.	1.4	6
377	Feasibility and Safety of Lung Cancer Screening and Prevention Program During the COVID-19 Pandemic. <i>Chest</i> , 2021, 160, e5-e7.	0.8	6
378	Surgery in soft tissue sarcoma: the thin line between a surgical or more conservative approach. <i>Future Oncology</i> , 2021, 17, 3-6.	2.4	6

#	ARTICLE	IF	CITATIONS
379	Sarcoma nomograms: a light over the darkness. <i>Oncoscience</i> , 2017, 4, 15-16.	2.2	6
380	Does screening for stage I lung cancer improve survival in a high-risk population?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 218-219.	4.3	5
381	Permeable Nonabsorbable Mesh for Total Diaphragmatic Replacement in Extended Pneumonectomy. <i>Annals of Thoracic Surgery</i> , 2017, 104, e105-e107.	1.3	5
382	Consistent Margin-Status Reporting in Soft Tissue Sarcoma Is Essential to Establish Risk-Adapted Strategies Integrating Biology and Histotype in Perioperative Treatments. <i>Journal of Clinical Oncology</i> , 2018, 36, 2357-2358.	1.6	5
383	Extra-pleural pneumonectomy. <i>Journal of Thoracic Disease</i> , 2019, 11, 1022-1030.	1.4	5
384	Prognostic value of microscopic evaluation of organ infiltration and visceral resection margins (VRM) in patients with retroperitoneal sarcomas (RPS).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11074-11074.	1.6	5
385	Prognostic stratification using the nomogram sarcuator and its impact on study results in a randomized controlled trial (RCT) for localized soft tissue sarcomas (STS): A secondary analysis of the EORTC-STBSG 62931.. <i>Journal of Clinical Oncology</i> , 2018, 36, 11518-11518.	1.6	5
386	Staging systems and nomograms in soft tissue sarcoma: outcome prediction by categorization or personalization?. <i>Chinese Clinical Oncology</i> , 2019, 8, S12-S12.	1.2	5
387	Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wall: Outcome Improvement Over Time at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 3274-3286.	1.5	5
388	Treatment modalities and long-term outcomes of hepatic hemangioendothelioma in the United States. <i>Hpb</i> , 2022, 24, 1688-1696.	0.3	5
389	Cancer registries and randomised clinical trials in rare tumours: At the two extremes of daily clinical practice. <i>European Journal of Cancer</i> , 2016, 64, 113-115.	2.8	4
390	Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors?. <i>Annals of Surgical Oncology</i> , 2017, 24, 1153-1156.	1.5	4
391	Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. <i>BMC Medicine</i> , 2017, 15, 160.	5.5	4
392	Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. <i>Modern Pathology</i> , 2018, 31, 160-168.	5.5	4
393	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	4.1	4
394	Head and neck adult-type soft tissues sarcomas: survival analysis and comparison between the last two editions of the TNM staging system. <i>European Archives of Oto-Rhino-Laryngology</i> , 2021, 278, 3003-3010.	1.6	4
395	Innate inflammatory markers for predicting survival in retroperitoneal sarcoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 1655-1661.	1.7	4
396	ASO Visual Abstract: An Analysis ofÂDifferentiationÂChangesÂand Outcomes at theÂFirstÂRecurrence of RetroperitonealÂLiposarcoma by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Annals of Surgical Oncology</i> , 2021, 28, 490-491.	1.5	4

#	ARTICLE	IF	CITATIONS
397	Dedifferentiation within well-differentiated liposarcoma of the extremity or trunk: Implications for clinical management. <i>Journal of Surgical Oncology</i> , 2021, 124, 838-845.	1.7	4
398	Abdominosacral resection for locally recurring rectal cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 770.	1.5	4
399	Lung cancer stage is an independent risk factor for surgical mortality. <i>Tumori</i> , 2008, 94, 362-9.	1.1	4
400	Residual Adrenal Function After Multivisceral Resection With Adrenalectomy in Adult Patients. <i>JAMA Surgery</i> , 2022, , .	4.3	4
401	The evolution of adjuvant/neoadjuvant trials for resectable localized sarcoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 17-27.	1.7	4
402	WHO Pathology. <i>Surgical Oncology Clinics of North America</i> , 2022, 31, 321-340.	1.5	4
403	Chemotherapy in patients with localized angiosarcoma of any site: A retrospective european study. <i>European Journal of Cancer</i> , 2022, 171, 183-192.	2.8	4
404	Prolonged Remission of Disseminated Atypical Adenomatous Hyperplasia Under Gefitinib. <i>Journal of Thoracic Oncology</i> , 2009, 4, 266-267.	1.1	3
405	Leiomyosarcoma and sarcoma with myogenic differentiation. <i>Cancer</i> , 2012, 118, 5349-5357.	4.1	3
406	A sommelier to guide wine selection and a specialist to manage the sarcoma patient: Barriers to referral and definition of a sarcoma specialist. <i>Journal of Surgical Oncology</i> , 2020, 121, 925-926.	1.7	3
407	Postnephrectomy outcomes following <i>en bloc</i> resection of primary retroperitoneal sarcoma: multicentre study. <i>British Journal of Surgery</i> , 2022, 109, 165-168.	0.3	3
408	Primary mesenteric sarcomas: Collaborative experience from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). <i>Journal of Surgical Oncology</i> , 2021, 123, 1057-1066.	1.7	3
409	Sunitinib malate in advanced alveolar soft part sarcoma (ASPS): A final update after the closure of the named use program.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10562-10562.	1.6	3
410	The sarculator stratified prognosis of patients with high-risk soft tissue sarcomas (STS) of extremities and trunk wall treated with perioperative chemotherapy in a randomised controlled trial (RCT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 11016-11016.	1.6	3
411	Trabectedin and radiotherapy in soft-tissue sarcoma (TRASTS) study: An international, prospective, phase I/II trial—A collaborative Spanish (GEIS), Italian (ISG), and French (FSG) groups study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11061-11061.	1.6	3
412	Effect of Preoperative Treatment on the Performance of Predictive Nomograms in Primary Retroperitoneal Sarcoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2304.	1.5	3
413	Extended surgery for retroperitoneal sarcoma: the key to maximizing the potential for cure and survival. <i>Pro. Oncology</i> , 2013, 27, 640, 642.	0.5	3
414	How to treat liposarcomas located in retroperitoneum. <i>European Journal of Surgical Oncology</i> , 2022, , .	1.0	3

#	ARTICLE	IF	CITATIONS
415	First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis. <i>Cancer</i> , 2022, 128, 2932-2938.	4.1	3
416	Refining Strategies to Identify Populations to Be Screened for Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2015, 25, 217-221.	1.0	2
417	The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. <i>Updates in Surgery</i> , 2016, 68, 321-323.	2.0	2
418	Surgery for recurrence in retroperitoneal leiomyosarcoma: Is it all about selection?. <i>Journal of Surgical Oncology</i> , 2017, 116, 267-268.	1.7	2
419	Long-Term Results of Thoraco-Pleuro-Pneumonectomy (TPP) for Recurrent Thoracic Sarcomas. <i>Annals of Surgical Oncology</i> , 2017, 24, 551-554.	1.5	2
420	Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients. <i>Toxicology in Vitro</i> , 2018, 50, 124-136.	2.4	2
421	Synovial sarcomas of the upper aero-digestive tract: is there a role for conservative surgery?. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2018, 26, 94-101.	1.8	2
422	Retroperitoneal sarcomas: Big tumors that involve more than just "Getting it Out". <i>Journal of Surgical Oncology</i> , 2018, 117, 5-6.	1.7	2
423	Surgical resection as an adjuvant to tyrosine kinase inhibitors in metastatic GIST: Association or causation?/Are we any closer to an answer?. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1287-1288.	1.0	2
424	Towards the standard use of (neo)adjuvant chemotherapy in selected localised soft tissue sarcoma at high risk of relapse: are we finally getting there?. <i>European Journal of Cancer</i> , 2018, 101, 251-253.	2.8	2
425	The evolving role of patient advocates in rare cancers: opportunities and challenges. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 1-3.	1.4	2
426	Post-surgical Regression of Thoracic Metastases After Salvage Lobectomy for Recurrent Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e284-e288.	1.9	2
427	Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2173-2181.	1.0	2
428	Predictive Value of MRP-1 in Localized High-Risk Soft Tissue Sarcomas: A Translational Research Associated to ISG-STs 1001 Randomized Phase III Trial. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2539-2552.	4.1	2
429	Long-term survival after salvage surgery for invasive thymoma with intracardiac extension. <i>Tumori</i> , 2008, 94, 772-6.	1.1	2
430	Morbidity of left pancreatectomy when associated with multivisceral resection for abdominal mesenchymal neoplasms. <i>JOP: Journal of the Pancreas</i> , 2011, 12, 138-44.	1.5	2
431	Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFR α and Bcl-2 expression in gastrointestinal stromal tumors. , 2010, 32, 225-33.		2
432	Risk of misclassification during diagnosis of malnutrition in retroperitoneal sarcoma patients. <i>Clinical Nutrition ESPEN</i> , 2022, 49, 459-465.	1.2	2

#	ARTICLE	IF	CITATIONS
433	First and further-line multidisciplinary treatment of retroperitoneal sarcomas. Current Opinion in Oncology, 2022, 34, 328-334.	2.4	2
434	Sacro-coccygeal chordoma: Diagnosis and treatment review. Seminars in Colon and Rectal Surgery, 2004, 15, 26-32.	0.3	1
435	Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. Annals of Surgical Oncology, 2015, 22, 2815-2816.	1.5	1
436	First- and second-line systemic treatments for metastatic and locally advanced soft tissue sarcomas in adults. The Cochrane Library, 0, , .	2.8	1
437	ASO Author Reflections: Evolving Concepts for Radiation Therapy in Extremity and Trunk Soft Tissue Sarcoma. Annals of Surgical Oncology, 2018, 25, 942-943.	1.5	1
438	ASO Author Reflections: Moving the Needle in Extremity and Trunk Soft Tissue Sarcoma. Annals of Surgical Oncology, 2020, 27, 899-900.	1.5	1
439	ASO Author Reflections: Reexcision after Macroscopically Complete Unplanned Excision in Extremity and Trunk Wall Soft Tissue Sarcoma: Is Less More?. Annals of Surgical Oncology, 2021, 28, 4718-4719.	1.5	1
440	ASO Author Reflections: Selecting Patients for Recurrent Retroperitoneal Sarcoma Surgery: The Challenging Trade-Off Between Oncologic Outcome and Morbidity. Annals of Surgical Oncology, 2021, 28, 852-853.	1.5	1
441	Immune contexture in high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STS-1001 randomized trial.. Journal of Clinical Oncology, 2021, 39, 11572-11572.	1.6	1
442	Recurrent neck myxofibrosarcoma: a case report. Journal of Medical Case Reports, 2021, 15, 484.	0.8	1
443	Sunitinib (SM) in advanced extraskeletal myxoid chondrosarcoma (EMC): Updated analysis in 11 patients (pts).. Journal of Clinical Oncology, 2016, 34, 11059-11059.	1.6	1
444	Retroperitoneal Sarcoma Involving the Inferior Vena Cava. , 2017, , 61-74.		1
445	ASO Author Reflections: Understanding the Impact of Primary Retroperitoneal Sarcoma Resection on Patient Well-being: One Step Forward in Learning How Caring for Patients is as Important as Curing Their Cancers. Annals of Surgical Oncology, 2021, 28, 3917-3918.	1.5	1
446	ASO Author Reflections: Outcome Improvement Over Time in Extremity and Trunk Wall Soft Tissue Sarcomas: To Whom the Merit?. Annals of Surgical Oncology, 2022, 29, 3287.	1.5	1
447	Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. Cancers, 2022, 14, 2624.	3.7	1
448	Desmoid Tumors. , 2022, , 619-627.		1
449	Retroperitoneal Liposarcoma: An Aggressive Strategy to Maximize Disease Control. International Journal of Radiation Oncology Biology Physics, 2017, 98, 273-274.	0.8	0
450	Soft Tissue Tumors of the Groin and Inguinal Region. , 2018, , 123-157.		0

#	ARTICLE	IF	CITATIONS
451	ASO Author Reflections: A Breach in the Borderâ€”Retroperitoneal Sarcoma with an Intraperitoneal Component. <i>Annals of Surgical Oncology</i> , 2019, 26, 838-839.	1.5	0
452	Principles of Local Therapy of Soft Tissue Neoplasms. , 2019, , 55-65.		0
453	Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2039-2041.	1.1	0
454	Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals. <i>Cancer</i> , 2020, 126, 4615-4616.	4.1	0
455	Gastrointestinal Stromal Tumors (GISTs). <i>UNIPA Springer Series</i> , 2021, , 1021-1059.	0.1	0
456	Towards a Global Collaboration: the Trans-Atlantic Retroperitoneal Sarcoma Working Group. <i>Updates in Surgery Series</i> , 2019, , 173-178.	0.1	0
457	History of Surgery in Retroperitoneal Sarcomas. <i>Updates in Surgery Series</i> , 2019, , 1-7.	0.1	0
458	Predicting the Risk of Recurrence in Retroperitoneal Sarcoma. <i>Updates in Surgery Series</i> , 2019, , 143-153.	0.1	0
459	Volume-Outcome Relationship in Surgery of Soft Tissue Sarcomas. <i>Updates in Surgery Series</i> , 2021, , 67-84.	0.1	0
460	ASO Visual Abstract: Refining the Approach to Patients with Primary Soft Tissue Sarcoma of the Extremities and Trunk Wallâ€”Outcome Improvement over Time at a Single Institution. <i>Annals of Surgical Oncology</i> , 2022, 29, 3289.	1.5	0
461	So Now What? Unanswered Questions Regarding Retroperitoneal Sarcomas, Hospital Volume, Multidisciplinary Expertise, and Outcomes. <i>Annals of Surgical Oncology</i> , 2022, 29, 2138.	1.5	0
462	Overall survival in abdominal wall sarcoma treated with curative intent surgery: A retrospective study from two European referral centres. <i>Journal of Surgical Oncology</i> , 2022, , .	1.7	0